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The bacterial exotoxins staphylococcal enterotoxin A and B (SEA and SEB) mediate disease
through their effects on T lymphocytes. In this manuscript we have demonstrated that both SEA
and SEB can directly activate purified T cells in the absence of accessory cells as determined by
a transition from Go to G, and induction of IL-2 receptor expression. However, neither SEA nor
SEB alone was sufficient to result in T-cell proliferation. The induction of T-cell proliferation by
SEB or SEA required the addition of a second costimulatory signal. This could be provided by
either accessory cells or monoclonal antibody stimulation of CD28. As previously reported, T-
cell proliferation induced by enterotoxin in the presence of accessory cells was partially inhibited
by a blocking antibody against class II MHC. In contrast, in purified T cells when costimulation
was provided through CD28, proliferation was not inhibited by class II antibody, and HLA-DR
expression was not detectable. In addition, costimulation through CD28 was partially resistant
to the effects of cyclosporin A. These results demonstrate that CD28 costimulation is sufficient
to induce proliferation of enterotoxin-activated T cells, and that this effect is independent of class
I1 MHC expression. o 1992 Academic press,  IK.
INTRODUCTION
In order for T cells to be activated by conventional antigens, the antigen must first
be processed and presented by an antigen presenting cell (APC). This requires pro-
teolysis of the antigen and incorporation of the resulting peptide  fragments into the
binding groove of an MHC molecule. The antigen-MHC complex is expressed on the
surface of the APC where it can be recognized by T cells bearing a T-cell receptor
(TCR) with the appropriate specificity (for review see (1)). This interaction leads to
TCR-mediated signal transduction events that initiate T-cell activation. However,
recent evidence suggest that TCR stimulation alone is an insufficient stimulus to lead
to T-cell proliferation (2,3). This observation has led to the hypothesis that an additional
signal(s) provided by the APC is required to induce T-cell proliferation. In the absence
of this second signal, the T cell will not proliferate and may be rendered refractory to
further antigenic challenge (4).
The CD28 signal transduction pathway has been identified as a potential candidate
for providing the second signal necessary for successful T-cell activation. If T cells are
activated using submitogenic doses of anti-CD3 monoclonal antibodies, they can be
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stimulated to proliferate by antibody stimulation of CD28 (5). A natural ligand for
CD28 has recently been identified and is the B7/BB 1 antigen on the surface of activated
B cells and interferon-y-induced macrophages (6). Costimulation of cells with sub-
mitogenic doses of Con A and B7-transfected  CHO cells can also induce T-cell pro-
liferation (7). Although these results show synergy between TCR or mitogen activation
and the CD28 activation pathway, neither means of primary activation are able to
mimic antigen activation events that might occur in vivo.
Recently, an interesting group of protein antigens termed superantigens has been
characterized which is capable of activating large numbers of peripheral blood T cells.
Unlike nominal antigens which activate on the order of 1 in 10,000 cells, superantigens
may activate anywhere from 10 to 30% of T cells. Bacterially derived superantigens
include the staphylococcal enterotoxins A and B (SEA and SEB), toxic shock syndrome
toxin 1, exfoliative toxin, and other bacterial proteins (8). In addition, the MIS antigens
have recently been characterized to be superantigens which appear to be encoded in
a unique open reading frame of some murine retroviruses (9-l 1). The ability of su-
perantigens to activate such a large percentage of T cells is due to their specificity for
all T cells which bear a particular V region on the fi chain of the TCR (8). Superantigens
have also been shown to bind to class II MHC molecules. Superantigens appear to
bind MHC outside the peptide binding groove (12). Traditional processing is not
required for binding to MHC. In fact, chemically fixed APC retain their ability to
bind and present superantigen (13, 14). It is thought, however, that the ability of
superantigens to stimulate T cells is dependent upon the TCR interacting with the
superantigen presented on the surface of an APC. Although this result has been in-
terpreted to mean that the required interaction between the T cell and APC is a TCR-
superantigen-MHC class II complex, APCs can also express other costimulatory mol-
ecules such as B7 which could potentiate a T cell’s response to superantigens. Consistent
with this possibility, unlike nominal antigen responses, superantigen responses are not
restricted to APCs that express self-encoded MHC molecules. In fact, even APC
expression of xenogeneic class II MHC has been shown to support enterotoxin-induced
T-cell proliferation (15).
This lack of stringency in the MHC requirement for T-cell activation by superantigen
suggested that there might be an additional or alternative role played by the accessory
cell. We therefore chose to investigate the effect of the CD28 activation pathway on
the responses of purified T cells to superantigen activation. In this manuscript, we
demonstrate that CD28 costimulation synergizes with superantigen to activate T cells
in a class II-independent manner. Our data indicate that superantigens are capable of
directly stimulating the T cell to enter the G1 phase of the cell cycle in the absence of
MHC presentation, and that provision of a second signal through CD28 allows full
progression through the cell cycle.
MATERIALS AND METHODS
Isolation of T cells. Peripheral blood was drawn from normal human volunteers.
The mononuclear cell fraction was obtained by density gradient centrifugation through
a Ficoll-Hypaque (Pharmacia) cushion. This fraction was used in experiments utilizing
peripheral blood mononuclear cells (PBMCs).  Purified resting T cells were obtained
by incubating the mononuclear cells with an antibody cocktail directed against B cells,
monocytes, and activated T cells. The antibody-coated cells were then removed by
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incubation with a goat anti-mouse immunoglobulin-coated magnetic beads (Advanced
Magnetics Inc.) as previously described (16). This method has routinely yielded a
population >99% CD2+ by flow cytometry.
Proliferation assays. Proliferation was measured by culturing 5 X 10’ purified T
cells or PBMCs  in each well of a 96-well microtiter plate. The final culture volume
was 200 ~1 of RPM1 1640 (GIBCO) supplemented with 10% FCS, penicillin (100 U/
ml), streptomycin (100 pg/ml), and 2 m&Y L-glutamine. SEA, SEB (Toxin Technol-
ogies), and cyclosporin A (Sandoz) were added in the indicated doses at the initiation
of the culture. Anti-CD28 monoclonal antibody (mAb 9.3, gift from J. Ledbetter),
anti-HLA-DR monoclonal antibody (mAb L243, gift from J. Ledbetter), and anti-
HLA-DQ monoclonal antibodies (mAbs 309 1, 3 101, 3 102, 3 120, kind gift of E. Mil-
ford) were added at the start of the culture period. Tritiated thymidine ([3H]TdR,
ICN) was included at a concentration 1 &i per well for the final 8 hr of the culture.
The cells were harvested onto glass microfiber filter strips (Whatman) after 72 hr using
a PHD cell harvester (Cambridge Technologies) and counted on a liquid scintillation
counter (LKB).  All values are expressed as the mean cpm * standard deviation of
triplicate or quadruplicate cultures.
Flow cytometry. One-milliliter cultures of T cells were incubated with medium
alone, SEA (100 rig/ml),  or SEB ( 1 pg/ml), SEA or SEB plus anti-CD28 antibody ( 1
pg/ml), or PMA (3 rig/ml)  plus anti-CD28 antibody (1 pg/ml) at 37°C for 72 hr.
Aliquots of each sample were stained with acridine orange (Polysciences) for cell cycle
analysis ( 17) FITC-conjugated anti-IL2 receptor antibody (Coulter), FITC-conjugated
anti-HLA-DR antibody (Becton-Dickinson), or an isotype-matched irrelevant antibody
(Becton-Dickinson). Each sample was analyzed on a FACScan  flow cytometer (Becton-
Dickinson).
RESULTS
CD28 provides costimulatory activity for superantigen-activated puriJied T cells.
Highly purified T cells were cultured with graded concentrations of either SEA (0.1
rig/ml to 1 .O fig/ml) or SEB (0.0 1 to 100 pg/ml). Replicate cultures were prepared in
which a stimulatory antibody to CD28 was added. Cultures were then assayed for
[3H]TdR  incorporation after 72 hr of culture. As shown in Fig. 1, treatment with SEB
alone failed to induce thymidine incorporation above control cultures. However, the
addition of anti-CD28 antibody resulted in significant proliferation to graded doses
of SEB. Treatment with anti-CD28 antibody alone had no effect (data not shown).
The lack of accessory cells was verified by an absence of proliferation to PHA. Identical
results were obtained using SEA (Fig. 3A and data not shown).
Stimulation with SEA or SEB leads to cell cycle entry. Since CD28 stimulation
alone does not induce T-cell cycle entry, the observation that CD28 provided costimu-
latory activity for T cells treated with either SEA or SEB suggested that these enter-
otoxins could induce cell cycle entry in purified T cells. In order to examine this we
stimulated purified T-cell cultures with SEB alone or with SEB plus anti-CD28 mono-
clonal antibody and stained the cells with acridine orange for cell cycle analysis. Un-
stimulated cells were run simultaneously in order to determine the Go/G,  interface.
Concomitantly, aliquots were stained with FITC-conjugated anti-IL-2 receptor anti-
body. As shown in Fig. 2, treatment with enterotoxin alone for 48 hr resulted in
progression of greater than 10% of the T cells from Go to G, as determined by an
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FIG. 1. Purified resting T cells were stimulated with graded concentrations of SEB alone or SEB plus anti-
CD28 antibody. The cultures were pulsed with [3H]TdR  for the final 8 hr of a 72-hr  culture and incorporated
thymidine determined by liquid scintillation counting as described under Materials and Methods. Each
condition was performed in quadruplicate, and the data are presented as the means + standard deviation.
Control cultures treated with PHA 5.0 pg/ml did not incorporate significant amounts of [3H]TdR  verifying
accessory cell depletion.
increase in RNA staining with no increase in DNA content. Similarly, enterotoxin
alone induced IL-2 receptor expression in 15% of the cells at 72 hr. In contrast, when
the anti-CD28 monoclonal antibody was present, a significant proportion of the cells
that had left the Go stage of the cell cycle were found to have increased their DNA
content and thus are in either the S or GzM  phases of the cell cycle. These data indicate
that stimulation with SEB alone is sufficient to activate the T cell but delivers an
inadequate signal for complete progression through the cell cycle. Provision of a second
signal by simultaneous stimulation of the CD28 pathway allowed the cell to progress
to S phase and proliferate.
Proliferation of T cells stimulated by SEA and anti-CD28 antibody is resistant to
cyclosporin A. CD28 has been shown to utilize a signal transduction pathway that is
resistant to the effects of cyclosporin A (CsA) when the initial signal is provided by
PMA, and partially resistant to CsA when cells are initially activated through the T-
cell receptor (16). In order to further examine the pathways involved in T-cell activation
by enterotoxin, we included cyclosporin A (1 pg/ml) in cultures activated by SEA and
SEA plus anti-CD28 antibody. As for SEB, SEA alone did not induce thymidine
incorporation whereas addition of antibody against CD28 resulted in significant pro-
liferation (Fig. 3A). Even in the presence of cyclosporin A there was a dose-dependent
increase in proliferation when cultures were activated by a combination of SEA and
anti-CD28 antibody (Fig. 3B). Control cultures activated with PMA plus anti-CD28
antibody were resistant to cyclosporin A and activation by PMA plus ionomycin was
sensitive to cyclosporin A (data not shown).
Activation by SEB plus anti-CD28 is independent of class II MHC. Previous work
has demonstrated that the staphylococcal enterotoxins are capable of simultaneously
binding the TCR and class II MHC molecules on the surface of antigen presenting
cells (18, 19). The observation that proliferation was not observed unless APCs  were
present in the culture was interpreted to mean that T-cell activation by superantigen
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FIG. 2. Purified resting T cells were treated with SEB (I &ml)  or SEB (I &ml)  plus anti-CD28 antibody
(1 fig/ml) for 48 hr and aliquots were stained with acridine orange for cell cycle analysis. Unstimulated cells
were analyzed simultaneously to determine the C&/G,  interface. Those with an increased RNA content but
unchanged DNA content were considered G,-phase cells. Cells with increases in both RNA and DNA
content were considered in S or GIM phases.
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FIG. 3. (A) Purified T cells were stimulated with graded concentrations of SEA alone or SEA plus anti-
CD28 antibody and [3H]TdR incorporation was determined as described under Materials and Methods. (B)
Identical cultures as in A were prepared with the addition of cyclosporin A (CsA; 1 &ml). Each point is
expressed as the mean + standard deviation. Proliferation of control cultures stimulated with PMA plus
ionomycin was inhibited by CsA, whereas the proliferation of cultures activated by PMA plus anti-CD28
antibody was resistant to CsA (data not shown).
is dependent upon class II MHC expression (14, 20, 21). Our observation that highly
purified T cells could be induced to proliferate by simultaneous stimulation with
enterotoxin and anti-CD28 antibody suggested that class II MHC may not be absolutely
required for superantigen activation of T cells. Alternatively, activated T cells can
express class II MHC and thus might provide class II-dependent superantigen presen-
tation to other T cells in trans. To examine this possibility, we included a blocking
antibody against HLA-DR, monoclonal antibody L243, in cultures of T cells and
PBMCs  activated by enterotoxin or enterotoxin plus anti-CD28 antibody (Fig. 4). No
significant proliferation was observed with SEB alone. As shown previously, inclusion
of anti-CD28 antibody allows SEB to induce T-cell proliferation in a dose-dependent
manner. There was no decrease in proliferation when anti-class II antibody was included
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FIG. 4. Purified resting T cells were treated with either SEB alone or SEB plus anti-CD28 antibody in the
presence or absence of a blocking monoclonal  antibody to HLA-DR, mAb  L243, and [3H]TdR incorporation
was determined. Each point is expressed as the mean f the standard deviation of triplicate or quadruplicate
cultures. Treatment with 5.0 &/ml  PHA did not result in an increase in [3H]TdR  over that of unstimulated
cells (data not shown).
in the cultures at doses of 1 .O or 10 pg/ml (data for 10 pg/ml not shown). In contrast,
the proliferation of PBMCs isolated from the same donor and stimulated with enter-
otoxin was significantly inhibited by anti-class II antibody (Fig. 5). To examine whether
HLA-DQ was involved in presentation of SEA or SEB to T cells, a cocktail of mono-
clonal antibodies that recognize all DQ alleles was added to cultures of enterotoxin
activated T cells and PBMCs (Table 1). Inclusion of the antibodies did not inhibit the
proliferation of purified T cells activated by SEA or SEB plus anti-CD28 but did
inhibit the proliferation of enterotoxin activated PBMCs. In addition, we examined
HLA-DR expression at 24 and 72 hr by purified T cells activated with SEA (0.1 or
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FIG. 5. Peripheral blood mononuclear cells were treated with SEB alone or SEB plus a blocking antibody
to HLA-DR, mAb L243. Incorporation of [‘H]TdR was determined as previously described. Each point
represents the mean + standard deviation.
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TABLE I
Effect of Anti-HLA-DQ
Experiment 1 Experiment 2
Purified T cell SEB 100 (&ml) Purified T cell SEA 1 .O (rig/ml)
Media 4,633 t 395 Media 1,594 t 108
+ aCD28 11,182 L 495 + czCD28 11,130 f 649
+ aCD28 + aDQ 10,910 f 1194 + oCD28 + aDQ 11,825 f 1228
t &D28 + (uDR 9,352 k 1196
+ cuCD28 + cuDQ/aDR 9,121 + 693
PBMCs SEA 1 .O (rig/ml)
Media 76,502 i- 7 156
+ olDQ 52,3  16 f 5839
t aDR 50,073 f 6314
+ OIDQ/(YDR 26,847 + 2306
Nole. Purified resting T cells were activated with SEA or SEB alone or in combination with anti-CD28
antibody. Antibodies to HLA-DR and/or HLA-DQ (28) were added at the start of culture as indicated and
proliferation measured at 72 hr as described under Material and Methods. Data are expressed as cpm, means
2 SD.
1 .O rig/ml)  with and without CD28 costimulation. There was no expression of HLA-
DR in either condition as determined by flow cytometry. This indicated that the T-
cell proliferation induced by enterotoxin plus anti-CD28 is not dependent on presen-
tation by an MHC class II molecule.
DISCUSSION
A substantial body of data has been accumulated describing the process of T-cell
activation by superantigens (8, 22). This family of proteins appears to be important
in a number of disease states. Bacterial exotoxins mediate the toxicity of staphylococcal
enteritis (23)  toxic shock syndrome (24),  and have been implicated in the pathogenesis
of rheumatoid arthritis (25). It has been suggested that expression of a superantigen
may mediate the T-cell depletion seen in HIV infection (26). An understanding of
their mechanisms of action will be crucial to developing effective therapeutic strategies.
The observation has been made by many laboratories that T-cell activation by
superantigen requires the presence of an APC in order to lead to T-cell proliferation
(20). The demonstration that superantigens are also capable of binding to class II
MHC molecules has led to the belief that class II is required for T-cell activation by
superantigen. However, one group has recently shown that superantigen can induce
T-cell cytotoxicity in a class II-independent system (27). In this paper we have treated
highly purified T cells with the superantigens SEA or SEB. The absence of accessory
cells has been demonstrated by the lack of proliferation to PHA and the absence of
MHC class II-positive cells as assayed by flow cytometry. Treatment of T cells with
SEA or SEB led to entry into the G, phase of the cell cycle and IL-2 receptor expression
but not proliferation. When an additional signal was provided to the T cells via stim-
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ulation of the CD28 pathway, the cells then went on to proliferate, as demonstrated
by incorporation of [3H]TdR  and increased DNA staining with flow cytometry. The
proliferation induced by enterotoxin plus CD28 stimulation was partially resistant to
the effects of cyclosporin A.
To verify that the observed proliferation was indeed independent of class II expres-
sion, we included monoclonal antibodies to HLA-DR and HLA-DQ in the cultures.
Both SEA and SEB have been shown to bind to HLA-DR (19). Proliferation of purified
T cells was unaffected by the addition of the antibody while PBMCs isolated from the
same individual and activated with enterotoxin alone were significantly inhibited.
Consistent with these data, SEA did not induce cell surface expression of HLA-DR.
The observation that PBMCs were partially inhibited by inclusion of a blocking
class II antibody implies a role for MHC molecules in T-cell activation by enterotoxin
in the presence of APCs. Several possible explanations exist. This may be in order to
facilitate an interaction of B7 with CD28 rather than an absolute requirement for class
II. Other possibilities are that the binding to MHC allows for more efficient crosslinking
of the TCR or that the binding to MHC actually induces B7 expression on the APC.
The data presented demonstrate that T cells can be activated and induced to enter
the G, phase of the cell cycle by enterotoxin in the absence of class II MHC expression
and that CD28 costimulation is sufficient to support proliferation in this circumstance.
It will now be important to determine whether this interaction is necessary for T-cell
activation by superantigen in viva Should this prove to be the case, it may lead to
new therapeutic strategies for superantigen-mediated disease.
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